KORU Medical Systems, Inc. (NASDAQ:KRMD – Get Free Report) has been given an average rating of “Moderate Buy” by the six research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $6.50.
KRMD has been the topic of a number of recent research reports. Wall Street Zen cut shares of KORU Medical Systems from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KORU Medical Systems in a report on Thursday, January 22nd. B. Riley Financial upped their price target on KORU Medical Systems from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $6.00 price objective on shares of KORU Medical Systems in a research report on Friday, March 13th. Finally, Lake Street Capital lifted their price objective on KORU Medical Systems from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, December 22nd.
View Our Latest Stock Analysis on KORU Medical Systems
Hedge Funds Weigh In On KORU Medical Systems
KORU Medical Systems Stock Up 1.2%
Shares of KRMD stock opened at $4.32 on Friday. The stock has a market cap of $200.32 million, a price-to-earnings ratio of -72.00 and a beta of 0.55. The business’s fifty day moving average is $4.73 and its 200 day moving average is $4.81. KORU Medical Systems has a twelve month low of $1.86 and a twelve month high of $6.61.
KORU Medical Systems (NASDAQ:KRMD – Get Free Report) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.02) by $0.01. KORU Medical Systems had a negative return on equity of 15.90% and a negative net margin of 6.41%.The business had revenue of $10.90 million during the quarter, compared to analyst estimates of $10.90 million. Equities research analysts expect that KORU Medical Systems will post -0.13 earnings per share for the current fiscal year.
About KORU Medical Systems
KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.
Read More
Receive News & Ratings for KORU Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KORU Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
